Novel fusion proteins of interferon α2b cause growth inhibition and induce jak-stat signaling in melanoma

Journal of Immunotherapy

Volumn 33, Issue 5, 2010, Pages 461-466

  Fernandes, Elroy ^a   Soans, Eroica ^a   Xu, Jianfeng ^a   Kieliszewski, Marcia ^a   Evans, Susan C ^b  

^a OHIO UNIVERSITY   (United States)

^b ARKANSAS STATE UNIVERSITY   (United States)

Author keywords

Fusion proteins; Interferon 2b; JAK STAT signaling; Melanoma

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA2 INTERFERON; ALPHA2B INTERFERON; ARABINOGALACTAN; INTERFERON RECEPTOR; JANUS KINASE; PROTEIN KINASE R; PROTEINASE; STAT PROTEIN; ALPHA INTERFERON; GALACTAN; HYBRID PROTEIN; JANUS KINASE 1; RECOMBINANT PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL VIABILITY; CONTROLLED STUDY; DERIVATIZATION; ENZYME DEGRADATION; ENZYME INDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOLECULAR SIZE; MOLECULAR WEIGHT; PLANT CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; PURIFICATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; UNITED STATES; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENE DOSAGE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; PROTEIN ENGINEERING; PROTEIN STABILITY; TUMOR CELL LINE;

2',5'-OLIGOADENYLATE SYNTHETASE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; EIF-2 KINASE; GALACTANS; GENE DOSAGE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; JANUS KINASE 1; MELANOMA; PROTEIN ENGINEERING; PROTEIN STABILITY; RECEPTORS, INTERFERON; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 77953051079     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181d32e59     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2006;56:106-130.
2. Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006;24:3164-3171.
3. Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2005;23:9001-9007.
4. Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995;64:621-651.
5. Wong LH, Krauer KG, Hatzinisiriou I, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem. 1997;272:28779-28785.
6. Heim MH. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res. 1999;19:75-120.
7. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117:1281-1283.
8. Pansky A, Hildebrand P, Fasler-Kan E, et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer. 2000; 85:720-725.
9. Martinez-Moczygemba M, Gutch MJ, French DL, et al. Distinct STAT structure promotes interaction of STAT2 with the p48 subunit of the interferon-alpha-stimulated transcription factor ISGF3. J Biol Chem. 1997;272:20070-20076.
10. Hovanessian AG, Justesen J. The human 2' to 5' oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2' to 5' instead of 3' to 5' phosphodiester bond formation. Biochimie. 2007;89:779-788.
11. Hovanessian AG. On the discovery of interferon-inducible, double-stranded RNA activated enzymes: the 2' to 5' oligoadenylate synthetases and the protein kinase PKR. Cytokine Growth Factor Rev. 2007;18:351-361.
12. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2:214-221.
13. Xu J, Tan L, Goodrum KJ, et al. High-yields and extended serum half-life of human interferon alpha2b expressed in tobacco cells as arabinogalactan- protein fusions. Biotechnol Bioeng. 2007;97:997-1008.
14. Ramon J, Saez V, Baez R, et al. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative. Pharm Res. 2005;22:1374-1386.
15. Wu X, Li X, Zeng Y, et al. Site-directed PEGylation of human basic fibroblast growth factor. Protein Expr Purif. 2006;48:24-27.
16. Yamamoto Y, Tsutsumi Y, Yoshioka Y, et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol. 2003;21:546-552.
17. Tsubery H, Mironchik M, Fridkin M, et al. Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J Biol Chem. 2004;279:38118-38124.
18. DeFrees S, Wang ZG, Xing R, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology. 2006;16:833-843.
19. Kieliszewski MJ, Shpak E. Synthetic genes for the elucidation of glycosylation codes for arabinogalactan-proteins and other hydroxyproline-rich glycoproteins. Cell Mol Life Sci. 2001;58: 1386-1398.
20. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002;54: 459-476.
21. Wang YS, Youngster S, Grace M, et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev. 2002;54:547-570.
22. Sangfelt O, Erickson S, Grander D. Mechanisms of interferoninduced cell cycle arrest. Front Biosci. 2000;5:D479-D487.
23. Lundblad D, Lundgren E. Block of glioma cell line in S by interferon. Int J Cancer. 1981;27:749-754.
24. Murphy D, Detjen KM, Welzel M, et al. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology. 2001;33:346-356.
25. Panniers LR, Clemens MJ. Inhibition of cell division by interferon: changes in cell cycle characteristics and in morphology of Ehrlich ascites tumour cells in culture. J Cell Sci. 1981;48:259-279.
26. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202: 8-32.
27. Magrassi L, De-Fraja C, Conti L, et al. Expression of the JAK and STAT superfamilies in human meningiomas. J Neurosurg. 1999;91:440-446.
28. Larner A, Reich NC. Interferon signal transduction. Biotherapy. 1996;8:175-181.
29. Carson WE. Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma. Clin Cancer Res. 1998;4:2219-2228.
30. Bromberg JF, Horvath CM, Wen Z, et al. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA. 1996;93:7673-7678.
31. Lupas A. Coiled coils: new structures and new functions. Trends Biochem Sci. 1996;21:375-382.
32. Berger B, Wilson DB, Wolf E, et al. Predicting coiled coils by use of pairwise residue correlations. Proc Natl Acad Sci U S A. 1995;92:8259-8263.
33. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6:975-990.
34. Zilberstein A, Kimchi A, Schmidt A, et al. Isolation of two interferon-induced translational inhibitors: a protein kinase and an oligo-isoadenylate synthetase. Proc Natl Acad Sci U S A. 1978;75:4734-4738.
35. Gale M Jr, Katze MG. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol Ther. 1998;78: 29-46.
36. Chelbi-Alix MK, Wietzerbin J. Interferon, a growing cytokine family: 50 years of interferon research. Biochimie. 2007;89: 713-718.